Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06192108 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 962
- Enrollment target
NCT06192108: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT06192108 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 962 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06192108, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 962 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Interventions
- DRUG Orforglipron
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 962 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 3 |
What the finished NCT06192108 record still lists
NCT06192108 is an interventional study that assigns participants to a tested intervention. The registered 962 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 2 interventions - of which Orforglipron is the first listed.
NCT06192108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06192108 about?
NCT06192108 is a clinical study titled "A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin". The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
What is the current status of trial NCT06192108?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 962 participants. The study started on 2024-01-10. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT06192108?
The interventions under investigation include: Orforglipron (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06192108?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06192108's enrollment target sits among peer trials
962 330th of 2000 higher than 1,671 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI